Recombinant antibodies are synthetic proteins created by combining different parts of antibody molecules from different sources. These molecules can be customized to target specific antigens, making them a powerful tool in the fields of medicine and biotechnology.
Traditional antibodies are made by the body's immune system to identify and neutralize foreign substances like bacteria or viruses. Recombinant antibodies, on the other hand, are designed in a laboratory to target specific molecules, such as those found on the surface of cancer cells.
One of the main advantages of recombinant antibodies is their ability to be produced on a large scale, making them useful in the development of diagnostic tools and therapeutic drugs. At Biointron, we specialize in creating high-quality recombinant antibodies through our fast and efficient platform.
Our team of experts can create recombinant antibodies from scratch, starting with gene synthesis all the way to protein purification. Our service is designed to accelerate your research and drug discovery projects with high-quality recombinant antibodies at an economical price.
The 15th Annual World Bispecifics Summit 2024 was held in Boston, MA on September 3-5, 2024. The event brought together experts in the field of bi, tri and multi-specifics, in addition to bispecific ADCs and BiTEs.
Antibodies are versatile molecules that perform a range of effector functions, many of which engage different arms of the immune system. Their modes of action extend beyond simple antigen binding, enabling the activation of various immune mechanisms that lead to pathogen neutralization and clearance. These functions include blocking molecular interactions, activating the complement system, and linking the humoral immune response to cellular immune responses via Fc receptor engagement.
In today’s competitive biotech landscape, intellectual property (IP) protection has become an essential pillar in fostering innovation and collaboration across drug discovery and development. By offering clear IP terms and no royalty fees,pharmaceutical companies and research institutes
